Oncology Sector In Review: Genmab
<p>March 24, 2010 (FinancialWire) — Genmab (OTC: GNMSF) (Copenhagen: GEN) reported Phase 3 results evaluating zalutumumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck, demonstrating a median OS …